Anti-Human IL1Beta Recombinant Antibody (Canakinumab) (CAT#: TAB-021)

Add to basket Submit an inquiry form Compare

• Tested Data
• Gene Expression
• Datasheet
• MSDS
• Publications
• COA

ELISA

Figure 1 Human IL1 Beta Therapeutic Antibody (TAB-021) in ELISA

ELISA analysis of TAB-021 was performed by coating with Recombinant Human IL1 Beta.

WB

Figure 2 Human IL1 Beta Therapeutic Antibody (TAB-021) in WB

Western blot analysis of TAB-021 was performed with Recombinant Human IL1 Beta.
Lane 1: Non-Reducing Antigen (1ug)
Lane 2: Reducing Antigen (1ug)

RNA Expression

Figure 1 RNA cell line category: Cell line enhanced.
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000125538-IL1B

Figure 1 RNA cell line category: Cell line enhanced.
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000125538-IL1B

 Datasheet

Peer-reviewed Publications

Our products have been used extensively by scientists all over the world to accelerate their life science research. Here, we present a collection of publications that cite this product.

Siu, Kam-Leung, et al. "Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC." The FASEB Journal (2019): fj-201802418R.

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Specifications

Product Property

Target

Related Resources

Rheumatoid Arthritis

Maturity Onset Diabetes of the Young

TNF Signaling Pathway

Product Notes

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Canakinumab"

Afuco™ Anti-IL1B ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-021)

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human IL1 beta. It is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.

DrugMonitor™ Anti-Canakinumab Antibody (VS-1224-YC249)

Canakinumab is a recombinant anti-human IL-1β monoclonal antibody marketed for treating Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). The DrugMonitor™ Anti-Canakinumab Antibody (VS-1224-YC249) is an anti-drug antibody (ADA) against Canakinumab. This drug-based antibody is raised in mice immunized with the Canakinumab. The anti-Canakinumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Canakinumab in samples.

See other products for "IL1B"

Customer Reviews and Q&As

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-021, RRID: AB_3111754)

Popular products with customers

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.